Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.46 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22483279 | 0.87 | HTR2A (0.56) | HTR2AHTR2CHTR7HTR6SIGMAR1 | |
| SCHEMBL7411682 | 0.85 | HTR2A (0.68) | HTR2ACACNA1GSIGMAR1HDAC1HDAC8 | |
| SCHEMBL22470270 | 0.85 | ALDH1A1 (0.50) | HTR2ACACNA1GHTR2CHTR7HTR6 | |
| Lithium Ion SCHEMBL22470304 | 0.85 | HTR2A (0.50) | HTR2AHTR2CHTR7HTR6SIGMAR1 | |
| SCHEMBL22470212 | 0.84 | HTR2A (0.52) | HTR2ACACNA1GHTR2CHTR7HTR6 | |
| SCHEMBL22470375 | 0.81 | HTR2A (0.46) | HTR2ACACNA1GSIGMAR1HDAC1HDAC8 | |
| SCHEMBL22483280 | 0.81 | HTR2A (0.46) | HTR2AHTR2CHTR7HTR6SIGMAR1 | |
| SCHEMBL22470259 | 0.77 | ALDH1A1 (0.62) | HTR2ACACNA1GSIGMAR1KMT2AMEN1 | |
| SCHEMBL19086400 | 0.76 | FAAH (0.56) | HTR2ASIGMAR1KMT2AMEN1 | |
| SCHEMBL18609760 | 0.74 | CA12 (0.57) | SIGMAR1CARM1PRMT6PRMT8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220151962-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-05-19 | — | — | US | disclosed |
| US-20220151962-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2022-05-19 | — | — | US | disclosed |
| EP-3941900-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | Deutsches Krebsforschungszentrum (DE) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020193431-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020193431-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151962-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 | HDAC10, HDAC1, HDAC11 | HTR2A 4528/4885CACNA1G 3794/4885HTR2C 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.